|
|
Exchange: |
New York Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
956,580,000 |
Market
Cap: |
784.72(B) |
Last
Volume: |
4,470,733 |
Avg
Vol: |
3,278,293 |
52
Week Range: |
$434.7 - $815.06 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
|
S&P 500 |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 720 |
Guru Rank Value : 1.4 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
656 |
Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
475,750 |
1,345,750 |
2,984,906 |
5,945,418 |
Total Sell Value |
$384,452,381 |
$992,137,761 |
$2,147,483,647 |
$2,147,483,647 |
Total People Sold |
2 |
2 |
4 |
6 |
Total Sell Transactions |
7 |
19 |
46 |
86 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Lilly Endowment Inc |
10% Owner |
|
2022-03-15 |
4 |
S |
$271.04 |
$60,511,869 |
D/D |
(220,075) |
106,633,810 |
|
-20% |
|
Lilly Endowment Inc |
10% Owner |
|
2022-03-14 |
4 |
S |
$269.21 |
$46,626,915 |
D/D |
(173,085) |
106,853,885 |
|
-22% |
|
Lilly Endowment Inc |
10% Owner |
|
2022-03-11 |
4 |
S |
$269.05 |
$5,875,986 |
D/D |
(21,840) |
107,026,970 |
|
-23% |
|
Lilly Endowment Inc |
10% Owner |
|
2022-03-10 |
4 |
S |
$266.29 |
$49,287,539 |
D/D |
(184,982) |
107,048,810 |
|
-21% |
|
Lilly Endowment Inc |
10% Owner |
|
2022-03-09 |
4 |
S |
$266.38 |
$5,335,148 |
D/D |
(20,018) |
107,233,792 |
|
-24% |
|
Lilly Endowment Inc |
10% Owner |
|
2022-03-04 |
4 |
S |
$260.69 |
$55,070,947 |
D/D |
(210,000) |
107,253,810 |
|
-24% |
|
Runge Marschall S |
Director |
|
2022-03-01 |
4 |
B |
$246.78 |
$49,850 |
D/D |
202 |
15,436 |
2.39 |
33% |
|
Jonsson Patrik |
SVP&Pres, LLY Imm, LLY USA&CCO |
|
2022-03-01 |
4 |
AS |
$247.56 |
$167,103 |
D/D |
(675) |
32,035 |
|
33% |
|
Hakim Anat |
SVP, GC & Secretary |
|
2022-03-01 |
4 |
D |
$249.95 |
$874,825 |
D/D |
(3,500) |
8,864 |
|
- |
|
Hakim Anat |
SVP, GC & Secretary |
|
2022-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,929 |
12,364 |
|
- |
|
Zakrowski Donald A |
Chief Accounting Officer |
|
2022-02-25 |
4 |
AS |
$243.84 |
$404,774 |
D/D |
(1,660) |
7,274 |
|
31% |
|
Luciano Juan R |
Director |
|
2022-02-22 |
4 |
A |
$239.13 |
$12,674 |
D/D |
53 |
13,591 |
|
- |
|
Fyrwald J Erik |
Director |
|
2022-02-22 |
4 |
A |
$239.13 |
$9,804 |
D/D |
41 |
68,883 |
|
- |
|
Greene Gabrielle E |
Director |
|
2022-02-22 |
4 |
A |
$239.13 |
$9,804 |
D/D |
41 |
761 |
|
- |
|
Alvarez Ralph |
Director |
|
2022-02-22 |
4 |
A |
$239.13 |
$11,239 |
D/D |
47 |
51,189 |
|
- |
|
Johnson Kimberly H |
Director |
|
2022-02-22 |
4 |
A |
$239.13 |
$9,565 |
D/D |
40 |
1,133 |
|
- |
|
Yuffa Ilya |
SVP & President, LLY Intl |
|
2022-02-16 |
4 |
AS |
$242.58 |
$242,580 |
D/D |
(1,000) |
11,624 |
|
29% |
|
Van Naarden Jacob |
SVP, CEO LoxoONC, Pres LlyONC |
|
2022-02-16 |
4 |
D |
$243.84 |
$533,034 |
D/D |
(2,186) |
7,967 |
|
- |
|
Van Naarden Jacob |
SVP, CEO LoxoONC, Pres LlyONC |
|
2022-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,461 |
10,153 |
|
- |
|
Yuffa Ilya |
SVP & President, LLY Intl |
|
2022-02-15 |
4 |
AS |
$237.45 |
$237,450 |
D/D |
(1,000) |
12,624 |
|
34% |
|
White Anne E. |
SVP & Pres-Lilly Neuroscience |
|
2022-02-09 |
4 |
A |
$243.27 |
$2,760,628 |
D/D |
11,348 |
50,352 |
|
- |
|
Fry Stephen F |
SVP, HR & Diversity |
|
2022-02-09 |
4 |
A |
$243.27 |
$3,001,709 |
D/D |
12,339 |
152,631 |
|
- |
|
Jonsson Patrik |
SVP&Pres, LLY Imm, LLY USA&CCO |
|
2022-02-09 |
4 |
A |
$243.27 |
$495,298 |
D/D |
2,036 |
32,710 |
|
- |
|
Pusey Leigh Ann |
SVP, Corp. Affairs & Comm. |
|
2022-02-09 |
4 |
A |
$243.27 |
$1,291,520 |
D/D |
5,309 |
26,244 |
|
- |
|
Hernandez Edgardo |
SVP & Pres., Mfg. Operations |
|
2022-02-09 |
4 |
A |
$243.27 |
$1,322,172 |
D/D |
5,435 |
20,610 |
|
- |
|
1437 Records found
|
|
Page 15 of 58 |
|
|